Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 10/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31207031 | 1.00 | FOLH1 (0.50) | FOLH1GSRRNPEPSLC6A5MMP2 | |
| SCHEMBL30427337 | 0.95 | FOLH1 (0.44) | FOLH1GSRRNPEPSLC6A5MMP2 | |
| SCHEMBL29894486 | 0.89 | FOLH1 (0.59) | FOLH1GSRRNPEPSLC6A5MMP2 | |
| SCHEMBL29390540 | 0.89 | FOLH1 (0.59) | FOLH1GSRRNPEPSLC6A5MMP2 | |
| SCHEMBL29669470 | 0.87 | FOLH1 (0.58) | FOLH1GSRRNPEPSLC6A5MMP2 | |
| SCHEMBL31418390 | 0.86 | FOLH1 (0.47) | FOLH1GSRRNPEPSLC6A5MMP2 | |
| SCHEMBL30030191 | 0.86 | FOLH1 (0.47) | FOLH1GSRRNPEPSLC6A5MMP2 | |
| SCHEMBL31418389 | 0.86 | FOLH1 (0.47) | FOLH1GSRRNPEPSLC6A5MMP2 | |
| SCHEMBL30168351 | 0.85 | FOLH1 (0.50) | FOLH1GSRRNPEPSLC6A5MMP2 | |
| SCHEMBL28171539 | 0.84 | CPB2 (0.49) | FOLH1GSRRNPEPSLC6A5CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 780 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3395373-B1 | METHOD FOR LABELLING A BIOLOGICAL TARGETING MOLECULE VIA CONJUGATION WITH A RADIOISOTOPE SUITABLE FOR PET OR SPECT IMAGING | GE HEALTHCARE LTD (GB) | 2022-10-19 | — | — | EP | claimed |
| US-10548995-B2 | Radiolabelling method | GE HEALTHCARE LIMITED (GB) | 2020-02-04 | — | — | US | claimed |
| EP-3036208-B1 | RADIOLABELLING METHOD | GE HEALTHCARE LTD (GB) | 2019-10-02 | — | — | EP | claimed |
| EP-3083526-B1 | PURIFICATION METHOD AND COMPOSITIONS | GE HEALTHCARE LTD (GB) | 2019-08-07 | — | — | EP | claimed |
| EP-3237614-B1 | NOVEL METHODS FOR DISPLAYING CYCLIC PEPTIDES ON BACTERIOPHAGE PARTICLES | LANTHIOPEP BV (NL) | 2019-06-26 | — | — | EP | claimed |
| EP-3395373-A1 | METHOD FOR LABELLING A BIOLOGICAL TARGETING MOLECULE VIA CONJUGATION WITH A RADIOISOTOPE SUITABLE FOR PET OR SPECT IMAGING | GE Healthcare UK Limited (GB) | 2018-10-31 | — | — | EP | claimed |
| EP-2646060-B1 | RADIOCONJUGATION METHOD | GE HEALTHCARE LTD (GB) | 2018-05-30 | — | — | EP | claimed |
| US-20170044080-A1 | RADIOCONJUGATION METHOD | GE HEALTHCARE LIMITED (GB) | 2017-02-16 | — | — | US | claimed |
| US-9493504-B2 | Radioconjugation method | GE HEALTHCARE LIMITED (GB) | 2016-11-15 | — | — | US | claimed |
| EP-3083526-A1 | PURIFICATION METHOD AND COMPOSITIONS | GE Healthcare UK Limited (GB) | 2016-10-26 | — | — | EP | claimed |
| WO-2006099026-A2 | METHOD AND COMPOSITIONS TO DECREASE SERUM CHOLESTEROL LEVELS | GENERAL MILLS, INC. (US) | 2006-09-21 | — | — | WO | claimed |
| US-4501760-A | EXTRUDING AN EMULSION OF PROTEIN MICELLES AND VEGATABLE OIL INTO HOT WATER | GENERAL FOODS, INC. (CA) | 1985-02-26 | — | — | US | claimed |
| US-4490397-A | MIXING STARCH WITH PROTEIN MICELLARS, THEN HOT EXTRUSION | GENERAL FOODS INC. (CA) | 1984-12-25 | — | — | US | claimed |
| US-4452782-A | IMMUNOPOTENTIATING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1984-06-05 | — | — | US | claimed |
| US-4424151-A | Heat gellable protein isolate | GENERAL FOODS INC. (CA) | 1984-01-03 | — | — | US | claimed |
| EP-0019072-B1 | PENTADECAPEPTIDE, PROCESS FOR THE PREPARATION THEREOF AND IMMUNOPOTENTIATING AGENT | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-09-14 | — | — | EP | claimed |
| US-4391750-A | Heat gellable protein isolate | GENERAL FOODS INC. (CA) | 1983-07-05 | — | — | US | claimed |
| US-4285862-A | FROM PLANTS | GENERAL FOODS, LIMITED (CA) | 1981-08-25 | — | — | US | claimed |
| EP-0019072-A1 | Pentadecapeptide, process for the preparation thereof and immunopotentiating agent | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1980-11-26 | — | — | EP | claimed |
| US-4035349-A | SULFHYDRYL AMINO ACIDS, ESTERS AND AMIDES, VEGETABLE PROTEIN | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 1977-07-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044080-A1 | RADIOCONJUGATION METHOD | GNRHR, KLK3, DUT | FOLH1 12/4885GSR 631/4885RNPEP 159/4885 |
| US-10548995-B2 | Radiolabelling method | QPCT, ARF5, PAICS | FOLH1 116/4885GSR 2446/4885RNPEP 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.